These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18504399)

  • 1. Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.
    Ishihara K; Kaneko M; Kitamura H; Takahashi A; Hong JJ; Seyama T; Iida K; Wada H; Hirasawa N; Ohuchi K
    Int Arch Allergy Immunol; 2008; 146 Suppl 1():7-10. PubMed ID: 18504399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors.
    Kaneko M; Ishihara K; Takahashi A; Hong J; Hirasawa N; Zee O; Ohuchi K
    Int Arch Allergy Immunol; 2007; 143 Suppl 1():28-32. PubMed ID: 17541273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of eosinophilic leukemia EoL-1 cells into eosinophils induced by histone deacetylase inhibitors.
    Ishihara K; Takahashi A; Kaneko M; Sugeno H; Hirasawa N; Hong J; Zee O; Ohuchi K
    Life Sci; 2007 Mar; 80(13):1213-20. PubMed ID: 17258775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
    Ishihara K; Kitamura H; Hiraizumi K; Kaneko M; Takahashi A; Zee O; Seyama T; Hong J; Ohuchi K; Hirasawa N
    Biochem Biophys Res Commun; 2008 Feb; 366(4):1007-11. PubMed ID: 18086564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils.
    Ishihara K; Hong J; Zee O; Ohuchi K
    Br J Pharmacol; 2004 Jul; 142(6):1020-30. PubMed ID: 15210580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
    Cools J; Quentmeier H; Huntly BJ; Marynen P; Griffin JD; Drexler HG; Gilliland DG
    Blood; 2004 Apr; 103(7):2802-5. PubMed ID: 14630792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
    Baumgartner C; Gleixner KV; Peter B; Ferenc V; Gruze A; Remsing Rix LL; Bennett KL; Samorapoompichit P; Lee FY; Pickl WF; Esterbauer H; Sillaber C; Superti-Furga G; Valent P
    Exp Hematol; 2008 Oct; 36(10):1244-53. PubMed ID: 18619723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
    Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
    Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
    Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P
    Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
    Sadovnik I; Lierman E; Peter B; Herrmann H; Suppan V; Stefanzl G; Haas O; Lion T; Pickl W; Cools J; Vandenberghe P; Valent P
    Exp Hematol; 2014 Apr; 42(4):282-293.e4. PubMed ID: 24407160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
    Li B; Zhang GS; Dai CW; Pei MF
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome.
    Jin Y; Chen Q; Lu Z; Chen B; Pan J
    Cancer Sci; 2009 Nov; 100(11):2210-7. PubMed ID: 19671059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.
    Fukushima K; Matsumura I; Ezoe S; Tokunaga M; Yasumi M; Satoh Y; Shibayama H; Tanaka H; Iwama A; Kanakura Y
    J Biol Chem; 2009 Mar; 284(12):7719-32. PubMed ID: 19147501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophil cell lines.
    Ishihara K
    Methods Mol Biol; 2014; 1178():45-51. PubMed ID: 24986606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.
    Lee JS; Lee NR; Kashif A; Yang SJ; Nam AR; Song IC; Gong SJ; Hong MH; Kim G; Seok PR; Lee MS; Sung KH; Kim IS
    Front Immunol; 2020; 11():1258. PubMed ID: 32903598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.
    Burgstaller S; Kreil S; Waghorn K; Metzgeroth G; Preudhomme C; Zoi K; White H; Cilloni D; Zoi C; Brito-Babapulle F; Walz C; Reiter A; Cross NC
    Leukemia; 2007 Dec; 21(12):2428-32. PubMed ID: 17914408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.
    Buitenhuis M; Verhagen LP; Cools J; Coffer PJ
    Cancer Res; 2007 Apr; 67(8):3759-66. PubMed ID: 17440089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.
    Capovilla M; Cayuela JM; Bilhou-Nabera C; Gardin C; Letestu R; Baran-Marzak F; Fenaux P; Martin A
    Eur J Haematol; 2008 Jan; 80(1):81-6. PubMed ID: 18028420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
    Jin Y; Ding K; Li H; Xue M; Shi X; Wang C; Pan J
    Mol Cancer; 2014 Jan; 13():17. PubMed ID: 24472312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.